NYSEAMERICAN:TOVX Theriva Biologics (TOVX) Stock Price, News & Analysis $0.25 +0.01 (+4.52%) Closing price 04:00 PM EasternExtended Trading$0.24 -0.01 (-2.32%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipSEC FilingsBuy This Stock About Theriva Biologics Stock (NYSEAMERICAN:TOVX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Theriva Biologics alerts:Sign Up Key Stats Today's Range$0.24▼$0.2550-Day Range$0.24▼$0.4152-Week Range$0.16▼$0.86Volume578,553 shsAverage Volume16.95 million shsMarket Capitalization$8.43 millionP/E RatioN/ADividend YieldN/APrice Target$1.00Consensus RatingBuy Company Overview Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland. Read More Theriva Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreTOVX MarketRank™: Theriva Biologics scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingTheriva Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialTheriva Biologics has a consensus price target of $1.00, representing about 313.2% upside from its current price of $0.24.Amount of Analyst CoverageTheriva Biologics has only been the subject of 1 research reports in the past 90 days.Read more about Theriva Biologics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Theriva Biologics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Theriva Biologics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTheriva Biologics has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.86% of the float of Theriva Biologics has been sold short.Short Interest Ratio / Days to CoverTheriva Biologics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Theriva Biologics has recently increased by 8.77%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTheriva Biologics does not currently pay a dividend.Dividend GrowthTheriva Biologics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Theriva Biologics this week, compared to 1 article on an average week.Search Interest12 people have searched for TOVX on MarketBeat in the last 30 days. This is an increase of 71% compared to the previous 30 days.MarketBeat Follows5 people have added Theriva Biologics to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Theriva Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders0.85% of the stock of Theriva Biologics is held by insiders.Percentage Held by Institutions6.17% of the stock of Theriva Biologics is held by institutions.Read more about Theriva Biologics' insider trading history. Receive TOVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theriva Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TOVX Stock News HeadlinesTheriva Biologics (NYSEAMERICAN:TOVX) Trading 0.7% Higher - Here's What HappenedJune 23 at 2:40 AM | americanbankingnews.comTheriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer ResearchJune 11, 2026 | globenewswire.comBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.June 26 at 1:00 AM | Chaikin Analytics (Ad)Theriva Biologics Faces Quorum Issue Delaying Warrant VoteJune 5, 2026 | tipranks.comAlliance Global Partners Sticks to Its Buy Rating for Theriva Biologics (TOVX)May 7, 2026 | theglobeandmail.comTheriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial ResultsMay 5, 2026 | globenewswire.comTheriva Biologics stock surges on AACR cancer trial dataApril 21, 2026 | investing.comTheriva Biologics Highlights Positive VCN-01 Pancreatic Cancer DataApril 20, 2026 | theglobeandmail.comSee More Headlines TOVX Stock Analysis - Frequently Asked Questions How have TOVX shares performed this year? Theriva Biologics' stock was trading at $0.2104 at the beginning of 2026. Since then, TOVX stock has increased by 15.0% and is now trading at $0.2420. How were Theriva Biologics' earnings last quarter? Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) announced its earnings results on Tuesday, May, 5th. The company reported ($0.05) earnings per share (EPS) for the quarter. The firm had revenue of $0.30 million for the quarter. When did Theriva Biologics' stock split? Shares of Theriva Biologics reverse split on the morning of Monday, August 26th 2024.The 1-25 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Theriva Biologics? Shares of TOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Theriva Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Theriva Biologics investors own include BIOLASE (BIOL), Jiuzi (JZXN), Dare Bioscience (DARE), Dermata Therapeutics (DRMA), Faraday Future Intelligent Electric (FFIE), Adial Pharmaceuticals (ADIL) and Aditxt (ADTX). Company Calendar Last Earnings5/05/2026Today6/26/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 TOVX's financial health is in the Green zone, according to TradeSmith. TOVX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:TOVX CIK894158 Webtherivabio.com Phone(301) 417-4364Fax301-417-4367Employees20Year FoundedN/APrice Target and Rating Average Price Target for Theriva Biologics$1.00 High Price Target$1.00 Low Price Target$1.00 Potential Upside/Downside+300.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($33.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.74 million Net MarginsN/A Pretax Margin-7,153.00% Return on Equity-178.29% Return on Assets-59.96% Debt Debt-to-Equity Ratio0.11 Current Ratio1.63 Quick Ratio1.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book0.54Miscellaneous Outstanding Shares33,740,000Free Float33,453,000Market Cap$8.43 million OptionableNot Optionable Beta1.10 The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSEAMERICAN:TOVX) was last updated on 6/26/2026 by MarketBeat.com Staff. From Our PartnersDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-car...Behind the Markets | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely, LLC | SponsoredElon Musk, Larry Fink & Brian Armstrong are ALL Piling into ThisElon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same te...Brownstone Research | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | Sponsored[Free Report] The 11-Hour Options Guide for Beginners - trade and ticker includedTired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredGold Will Hit $4,900JPMorgan now sees gold hitting $4,900, and central banks are buying at a record 710 tonnes per quarter. Trump'...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theriva Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theriva Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
